Zeo ScientifiX, Inc. (ZEOX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Zeo ScientifiX, Inc. (ZEOX) trades at $1.42 with AI Score 49/100 (Grade C). Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company focused on developing biological therapeutics for degenerative diseases. Market cap: $11.1M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for ZEOX: ZEOX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ZEOX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ZEOX: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Zeo ScientifiX, Inc. (ZEOX) Healthcare & Pipeline Overview
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company specializing in innovative biological therapeutics aimed at treating degenerative diseases, with a strong focus on regenerative medicine and advanced therapeutic solutions.
What Is the Investment Thesis for ZEOX?
Zeo ScientifiX, Inc. presents a unique investment thesis driven by its innovative product pipeline and strong market potential in the biotechnology sector. The company's lead candidate, Zofin, is in Phase I/II clinical trials, targeting significant health issues such as COVID-19 and chronic obstructive pulmonary disease, which could yield substantial revenue upon successful commercialization. Additionally, the proprietary technologies like Patient Pure X and topical products could diversify revenue streams and enhance market presence. With a gross margin of 81.6%, the company is well-positioned to capitalize on high-margin opportunities in the regenerative medicine sector. However, the current profit margin of -92.3% indicates ongoing operational challenges, which investors should monitor closely. The biotechnology industry is expected to grow at a CAGR of 7.4% through 2027, providing a favorable backdrop for Zeo ScientifiX's growth prospects.
Based on FMP financials and quantitative analysis
ZEOX Key Highlights
Market Cap of $11.1M indicates a small-cap company with potential for growth.
- Gross Margin of 81.6% suggests strong pricing power and operational efficiency.
- Profit Margin of -92.3% highlights the need for improved operational performance.
- Beta of 1.70 indicates higher volatility compared to the broader market.
- No dividend yield reflects the company's focus on reinvestment for growth.
Who Are ZEOX's Competitors?
ZEOX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| OCGN Ocugen, Inc. | $1.48 | +10.45% | $502M | — |
| AMRN Amarin Corporation plc | $14.06 | -2.23% | $291M | 51 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZEOX's Key Strengths?
Innovative product pipeline with potential for high market demand.
- Strong gross margin indicating operational efficiency.
- Expertise in regenerative medicine and biologic technologies.
What Are ZEOX's Weaknesses?
Current negative profit margin indicating operational challenges.
- Limited market presence due to being a small-cap company.
- Dependence on successful clinical trial outcomes for growth.
What Could Drive ZEOX Stock Higher?
ZEOX catalyst: Results from Phase I/II clinical trials for Zofin, which could significantly impact market perception and valuation.
- Development and commercialization of Patient Pure X, targeting the regenerative medicine market.
- Expansion of topical aesthetic product line, leveraging proprietary ingredients to capture market share.
What Are the Key Risks for ZEOX?
Financial-distress signal — its Altman Z-Score of -24.15 sits in the distress zone (elevated bankruptcy risk).
- Regulatory approval delays for clinical trials could hinder product launch timelines.
- Market competition from established biopharmaceutical companies may impact growth.
- Financial instability due to negative profit margins could limit operational flexibility.
What Are the Growth Opportunities for ZEOX?
- Growth opportunity 1: The ongoing clinical trials for Zofin, targeting COVID-19 and chronic obstructive pulmonary disease, represent a significant growth driver. The global market for COVID-19 therapeutics is projected to reach $50 billion by 2027, and successful trial outcomes could position Zeo ScientifiX as a key player in this lucrative segment.
- Growth opportunity 2: The regenerative medicine market is expected to grow to $63 billion by 2028, driven by increasing demand for advanced therapies. Zeo ScientifiX's innovative products like Patient Pure X could capture a share of this expanding market, particularly as healthcare providers seek effective solutions for tissue healing and inflammation reduction.
- Growth opportunity 3: The aesthetic medicine market is forecasted to grow at a CAGR of 10.6% through 2025. Zeo ScientifiX's topical products, including ZEO GROW X and EXO FOLLICLE FUEL, are positioned to benefit from this trend, as consumers increasingly seek non-invasive aesthetic treatments that leverage advanced biologics.
- Growth opportunity 4: Expansion into international markets could provide additional revenue streams for Zeo ScientifiX. As the company continues to develop its product offerings, entering markets in Europe and Asia, where demand for regenerative therapies is rising, could significantly enhance its growth potential.
- Growth opportunity 5: Collaborations and partnerships with larger pharmaceutical companies could accelerate product development and market entry. By leveraging the resources and distribution networks of established players, Zeo ScientifiX can enhance its operational capabilities and expedite its path to commercialization.
What Threats Does ZEOX Face?
- Regulatory hurdles in the biotechnology sector.
- Intense competition from established pharmaceutical companies.
- Market volatility impacting small-cap stocks.
What Are ZEOX's Competitive Advantages?
- Proprietary biologic technologies that differentiate product offerings.
- Strong focus on clinical research and development to drive innovation.
- Established expertise in regenerative medicine and tissue healing.
What Does ZEOX Do?
Founded in 2011 and headquartered in Davie, Florida, Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of biological therapeutics for degenerative diseases and regenerative medicine. Originally known as Organicell Regenerative Medicine, Inc., the company rebranded to Zeo ScientifiX, Inc. in February 2024 to better reflect its focus on innovative therapeutic solutions. The company’s flagship product, Zofin, is an acellular biologic therapeutic derived from perinatal sources, currently undergoing Phase I/II clinical trials aimed at treating COVID-19, chronic obstructive pulmonary disease, and knee osteoarthritis. In addition to Zofin, Zeo ScientifiX offers Patient Pure X, an autologous blood-derived biologic technology designed to enhance the body's natural ability to reduce cellular inflammation and promote tissue healing. The company also develops a range of products incorporating proprietary ingredients for topical aesthetic applications, including ZEO GROW X, a professional-grade formula that delivers concentrated doses of topical exosomes to support follicular function, as well as ZEO GROW BOOST and EXO FOLLICLE FUEL. With a small team of 20 employees, Zeo ScientifiX is positioned to leverage its unique biologic technologies to address significant unmet medical needs in both therapeutic and aesthetic markets.
What Products and Services Does ZEOX Offer?
- Develops biological therapeutics for degenerative diseases.
- Conducts clinical trials for innovative treatments like Zofin.
- Offers autologous blood-derived biologic technology through Patient Pure X.
- Creates topical aesthetic products utilizing proprietary ingredients.
- Focused on regenerative medicine and tissue healing solutions.
- Engages in research and development to advance therapeutic offerings.
How Does ZEOX Make Money?
- Generates revenue through the sale of biologic therapeutics and products.
- Engages in clinical trials to develop and commercialize new therapies.
- Utilizes proprietary technologies to create differentiated product offerings.
- Targets both therapeutic and aesthetic markets for revenue diversification.
What Industry Does ZEOX Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in technology and increasing demand for innovative therapeutic solutions. With a projected CAGR of 7.4% through 2027, the sector is expanding rapidly as companies like Zeo ScientifiX focus on developing biologics and regenerative therapies. The competitive landscape is characterized by a mix of established players and emerging startups, all vying for market share in therapeutic areas with significant unmet needs. Zeo ScientifiX's focus on degenerative diseases positions it favorably within this growing market, particularly as the demand for effective treatments continues to rise.
Who Are ZEOX's Key Customers?
- Healthcare providers seeking innovative treatment options.
- Patients with degenerative diseases or conditions requiring regenerative therapies.
- Aesthetic practitioners looking for advanced topical solutions.
- Research institutions interested in biologic technologies.
Company Profile
Zeo ScientifiX, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Davie, US. The company is led by CEO Ian T. Bothwell. ZEOX has traded publicly since 2016.
Key Financial Metrics
Return on equity for Zeo ScientifiX, Inc. stands at 455.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -99.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -12.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -35.7%, the inverse of the P/E and a quick read on earnings relative to price.
ZEOX Valuation & Market Position
With a $11.1M market cap, Zeo ScientifiX, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ZEOX's quantitative score of 49/100 is below the peer average of 70/100.
Quarterly Financial Performance: Zeo ScientifiX, Inc.
Revenue for Zeo ScientifiX, Inc. came in at $2.6M during Q2 2026, a 78.5% improvement versus the preceding quarter. The company recorded a net loss of $145K, with diluted EPS of $-0.02. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ZEOX averaged $-0.15 in diluted EPS.
Financial Health
Zeo ScientifiX, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -24.15 places it in the distress zone, a signal of elevated financial risk.
ZEOX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $3M | -$145,000 | -$0.02 |
| Q1 2026 | $1M | -$852,000 | -$0.12 |
| Q4 2025 | $2M | -$815,000 | -$0.12 |
| Q3 2025 | $1M | -$2M | -$0.32 |
Based on FMP financials and quantitative analysis
ZEOX Latest News
No recent news available for ZEOX.
ZEOX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZEOX.
Price Targets
Wall Street price target analysis for ZEOX.
ZEOX MoonshotScore
What does this score mean?
The MoonshotScore rates ZEOX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ian T. Bothwell
CEO
Ian T. Bothwell has extensive experience in the biotechnology sector, having held various leadership roles in clinical development and regulatory affairs. He holds a degree in Biomedical Engineering and has spent over a decade working with innovative biopharmaceutical companies focused on regenerative medicine.
Track Record: Under Ian's leadership, Zeo ScientifiX has successfully transitioned from Organicell Regenerative Medicine to a focused biopharmaceutical entity, positioning the company for future growth with a robust product pipeline.
ZEOX OTC Market Information
The OTC Other tier includes companies that do not meet the more stringent requirements of the OTCQX or OTCQB tiers. These companies may have limited financial disclosure and are generally less liquid than those listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure may hinder investor confidence.
- Lower liquidity can lead to higher volatility in stock price.
- Regulatory risks associated with clinical trials and product approvals.
- Verify the company's clinical trial status and results.
- Assess the management team's experience and track record.
- Examine the competitive landscape and market positioning.
- Review any available financial statements or reports.
- Investigate potential partnerships or collaborations.
- Established history since 2011 with a focus on biotechnology.
- Recent rebranding to reflect a strategic shift towards therapeutics.
- Development of proprietary technologies indicating innovation.
ZEOX Healthcare Stock FAQ
What does the AI Score mean for ZEOX?
ZEOX holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company focused on developing biological therapeutics for degenerative diseases. Its lead product, Zofin, targets multiple conditions …
What does Zeo ScientifiX, Inc. do?
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company that develops biological therapeutics for degenerative diseases and regenerative medicine. Its lead product, Zofin, is in clinical trials targeting conditions like COVID-19 and chronic obstructive pulmonary disease. The company also offers innovative technologies like Patient Pure X and a range of topical aesthetic products.
What are the main risks for ZEOX?
Zeo ScientifiX faces several risks, including potential regulatory approval delays that could impact the timeline for bringing products to market. Additionally, the company contends with ongoing competition from larger biopharmaceutical firms, which may affect its market share. Financial instability, highlighted by a negative profit margin, poses another risk that could limit operational flexibility and growth opportunities.
How does Zeo ScientifiX, Inc. navigate regulatory approval processes?
Zeo ScientifiX, Inc. follows a structured approach to navigate regulatory approval processes, focusing on compliance with FDA guidelines for clinical trials. The company engages with regulatory agencies throughout the development process to ensure adherence to safety and efficacy standards. This proactive strategy aims to mitigate potential delays and enhance the likelihood of successful product approvals.
What are the key factors to evaluate for ZEOX?
Zeo ScientifiX, Inc. (ZEOX) holds an AI score of 49/100 (low). presents a unique investment thesis driven by its innovative product pipeline and strong market potential in the biotechnology sector. Not financial advice.
How frequently does ZEOX data refresh on this page?
ZEOX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ZEOX's recent stock price performance?
Zeo ScientifiX, Inc. (ZEOX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline with potential for high market demand. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZEOX overvalued or undervalued right now?
Zeo ScientifiX, Inc. (ZEOX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ZEOX before investing?
Before investing in Zeo ScientifiX, Inc. (ZEOX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be limited due to the company's OTC classification.